Koen Keirse, MD RZ Tienen, Belgium

Similar documents
Treating in-stent occlusions with the Rotarex catheter : The ROBINSON study

PES BTK 70 : 12 m results with a paclitaxelcoated self-expanding stent in BTK arteries

RELINE-trial : 24 months results with the Viabahn vs PTA for in-stent restenosis

Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort

The Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD

Shockwave Medical Lithoplasty. Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany

Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria

12-Month and preliminary 24-month outcomes of combining a DCB with a modern generation of nitinol stent in fem-pop lesions. BIOLUX 4EVER study

Surgical Bypass or. Zilver PTX. 12 months preliminary data. LINC 2016, Leipzig. Marc Bosiers, MD. Marc Bosiers Koen Deloose Joren Callaert

Drug delivery devices for BTK treatment

Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry

Or is the ivolution stent a better alternative? EVOLUTION 12-month data

Does stent design influence the results of SFA stenting?

Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD

Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)

Christian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide

BIOLUX 4EVER : Combining Passeo-18 Lux DCB and Pulsar-18 BMS : 12 month results of full cohort

12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany

DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes

Atherectomy: Jetstream and Directional. George S. Chrysant, M.D.

Dealing with Calcification in BTK Arteries: Is Lithoplasty the Answer?

2-YEAR DATA SUPERA POPLITEAL REAL WORLD

Dierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany

Update from Korea on the Lutonix SFA registry 12 month data

The essentials for BTK procedures: wires, balloons, what else

The Freeway Stent Study: the 12 Months results highly favor the use of DEB in combination with stenting

BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort

DISRUPT PAD. (( Data Summary )) DISRUPT PAD Data Summary SPL Rev. B 2016 Shockwave Medical Inc. All rights reserved.

One Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller

COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions. Dierk Scheinert

Mechanical thrombectomy in peripheral interventions: A multitask and effective tool in a widening scenario. Current evidence and technical tips.

TOBA Trial 12 months Results

Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?

The Illumina FIH study with a next generation DES 12-months results

ISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany

Hiroshi Ando, MD Kasukabe Chuo General Hospital Saitama, Japan

The LIMBO trial: a RCT investigating adventitial dexamethasone infusion to prevent restenosis in BTK arteries utilizing a novel angiographic endpoint

Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)

How do I use mechanical debulking for the treatment of arterial occlusions

Michael K. W. Lichtenberg MD, FESC on behalf of KANSHAS 1 investigators; Tepe G, Müller-Hülsbeck S, Deloose K, Verbist J, Goverde P, Zeller T

Rotarex mechanical thrombectomythe first line option for thrombotic occlusions?

Surgical Bypass vs. Zilver PTX stent for long SFA lesions : Interim results of the ZilverPass Trial

Update on the Ranger clinical trial programme

PRISM Trial. Retrospective Case Review of Technical Success Using the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery

Preliminary 6-month results of VMI-CFA trial

TOBA II 12-Month Results Tack Optimized Balloon Angioplasty

DCB + stent in the SFA

How to perform CFA Supera deployment. Koen Deloose, MD Head Dept Vascular Surgery AZ Sint Blasius Dendermonde, Belgium

Outcome of DCB and PTA post stenting in occluded versus stenotic lesions subgroup analysis of the randomized Freeway Stent Study

2 Year Results from the MDT SFA Japan Trial - DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA

PATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA. Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE

New Data to Shape the Era of Drug Elution in Peripheral Interventions

OCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter. Patrick Muck, MD

Rotarex mechanical debulking: The Leipzig experience in patients

Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA

Hybrid Procedures for Peripheral Obstructive Disease - Step by Step -

EffPac - Trial: Assessment of the Effectiveness of DCB versus POBA in the SFA Ulf Teichgräber, MD, MBA

On behalf of the DURABILITY Investigators:

The Utility of Atherectomy and the Jetstream Atherectomy System

Comparison of Angiographic Dissection Patterns Caused by Long vs Short Balloons During Balloon Angioplasty for Chronic Femoropopliteal Occlusions

Catheter-Directed Thrombolysis for Acute Limb Ischemia. Hwan Jun Jae MD Seoul National University Hospital Seoul, Korea

LIFESTREAM TM First look at the BOLSTER 2-year follow up data

SFA CTO Lesion Management laser or directional atherectomy?

The Crack and Pave technique for highly resistant calcified lesions. Manuela Matschuck MD University Hospital Leipzig Department Angiology

Step by step Hybrid procedures in peripheral obstructive disease. Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery

Study of a Balloon-Expandable Covered Stent for Obstructive Lesions in the Iliac Artery

Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)

Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?

Acute Safety and Technical Results of the EverFlex Self-Expanding Stent with New Delivery System (ENTRUST)

ILLUMENATE FIH Direct DCB Cohort 12-Month Results

The results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan

Efficacy of DEB in Calcification and Subintimal Angioplasty

Long-term Zilver PTX Data from Japan: 5-year Results in the Real World

Luminor DCB in femoropopliteal lesions

Evolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data

CHALLENGING ILIAC ACCESSES AND THROMBOSIS PREVENTION

The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions

Use of Laser In BTK Disease (CLI)

Novel distal popliteal artery puncture technique in supine position for chronic femoropopliteal arterial occlusion; frontal popliteal puncture

SAVER: Rationale and merits for an all-comers DCB e-registry Frank Vermassen MD

Atherectomy with thrombectomy of. Rotarex S : The Leipzig experience

DCB level 1 evidence review

Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD

Lessons learnt from DES in the SFA is there any ideal concept so far?

Maximizing Outcomes in a complex population with Drug-coated balloon

Update on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria

When and how to use distal protection devices for lower extremity revascularization. Peter A. Schneider, MD Kaiser Foundation Hospital, Honolulu

Balloon Expandable Covered Stents. Suddenly a Crowded Space

Combination therapy : treatment rationale and clinical evidence

Micromesh technology in carotid artery treatment what is next? Max Amor MD Clinique Louis Pasteur, Essey-Les-Nancy France

Disclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA

Are Drug-coated balloons Durable? Level 1 evidence review. Koen Keirse, MD Vascular Surgery, RZ Tienen Tienen, Belgium

First time data release: Initial experience with the temporary Spur Stent System: DEEPER Trial first-in-man results Jihad A. Mustapha, MD, FACC,

Patient safety in the Eluvia DES and Ranger DCB programmes

XPEDITE Clinical Study PaclitaXel-coated Peripheral StEnts used In the Treatment of FemoropoplitEal Stenoses

Treatment options of late failures of EVAS. Michel Reijnen Rijnstate Arnhem The Netherlands

Angiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis-

Extreme SFA Lesions: DETOUR I 12- Month Results in Lesions >30cm. Sean Lyden, MD Chairman Vascular Surgery Cleveland Clinic Cleveland, Ohio

Transcription:

Clinical Benefits of the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection from the ENTRAP Study Koen Keirse, MD RZ Tienen, Belgium

Disclosure Speaker name: Koen Keirse... I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s) I do not have any potential conflict of interest

Embolization during Lower Extremity Interventions Rates of Macro-Embolization have been described as high at 38% after Fem-Pop PTA 1 Can be associated with Limb Loss 2 Risk of limb loss may be higher in patient with poor run-off and CLI 2,3 Higher rate of embolization for in-stent restenosis and chronic total occlusions compared with stenotic lesions 3 Higher rate of embolization in TASC C and D lesions compared with TASC A and B lesions 3 1 J Endovasc Ther. 2008 Jun;15(3):270-6. doi: 10.1583/08-2397.1. 2 Ann Vasc Surg. 2010 Jan;24(1):14-22. doi: 10.1016/j.avsg.2009.06.020. Epub 2009 Sep 11. 3 J Vasc Surg. 2011 Feb;53(2):347-52. doi: 10.1016/j.jvs.2010.09.008. Epub 2010 Dec 3.

Embolization after SFA PTA

Aspiration Thrombectomy after SFA PTA

Embolization after SFA CTO PTA

Embolization after SFA CTO PTA

Embolization after SFA CTO PTA

Embolization after SFA PTA

Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection

Vanguard System Design Features First system for lower extremities in which PTA balloon and EPD are coupled on same catheter Filter expandable to 8.0 mm by operator based on patient anatomy Sheathless Design Over-the-Wire PTA balloon catheter.018 Guidewire Compatible 6 French Sheath Compatible Balloon Diameters 4 8 mm Balloon Lengths: 40, 80, 120, 200 mm Filter membrane with 150 micron pores

Urethane Membrane Nitinol Frame Unexpanded Filter (membrane not shown) Gold radiopaque markers Expanded Filter (with membrane) Adjustable expansion of filter to 8 mm in diameter

Embolic Capture 2.5 mm diameter inlet 150 um filter holes

Capture Efficiency Bench Testing 93.1% Capture Efficiency Testing 212 250 um particles Minimal disruption of blood flow Captured Fluorescent Particles

ENTRAP Study A Single-Arm, Multicenter Study for the Lower Extremities using the VaNguard IEP TM Peripheral Balloon Angioplasty System with InTegRAted Embolic Protection prospective, non-randomized, study with follow-up to 30 days to determine acute safety, acute device performance and clinical performance Primary Safety Endpoint Primary Efficacy Endpoint Secondary Endpoints Freedom from MAE, defined as death, amputation and target vessel revascularization (TVR) at 30 days post-procedure. Procedural Success, defined as <50% residual stenosis without any MAE (death, amputation or TVR) prior to hospital discharge. 1. Technical success, defined as successful delivery, balloon inflation and deflation, subsequent EPD deployment and retrieval of the intact device. 2. Change in Ankle-Brachial Index (ABI) from baseline, discharge and 30 days. 3. Rutherford-Becker (RB) Improvement ( 1) at 30 days. 4. Filter content analysis post-removal

ENTRAP Study Sites Up to 130 subjects will be enrolled at sites in Germany and Belgium Investigator Prof. Thomas Zeller, MD Coordinating Principal Investigator Ralf Langhoff, MD Prof. Dierk Scheinert, MD Prof. Stefan Müller-Hülsbeck, MD Koen Deloose, MD Jürgen Verbist, MD Lieven Maene, MD Koen Keirse, MD Site Bad Krozingen, Germany Berlin, Germany Leipzig, Germany Flensburg, Germany Dendermonde, Belgium Bonheiden, Belgium Aalst, Belgium Tienen, Belgium

Risk of Distal Embolization during LE Vascular Interventions High Risk of Embolization Visible Thrombus in Vessel Acute Limb Ischemia Chronic Total Occlusions Ulceration/Calcification Long Lesions In-stent Restenosis High Consequence of Embolization Critical Limb Ischemia Single Vessel Run-off Diabetes Mellitus Severe/Diffuse Pedal Disease Multi-level Disease End-Stage Renal Disease

Vessel Prep in Patient with High Embolic Risk: Vanguard IEP System in SFA Filter deployed Images courtesy of Ralf Langhoff, M.D. Sankt Gertrauden Krankenhaus, Berlin, Germany Retrieved particles

Vanguard IEP Peripheral Balloon Angioplasty System with with Integrated Embolic Protection Filter

Vanguard Size Matrix

Conclusions Distal embolization can result in occlusion of distal vessels, lower extremity ischemia, tissue loss and amputation Not all patients have the same risk of distal embolization A novel balloon with integrated embolic protection and adjustable filter size may help mitigate the risk of distal embolization in high-risk patients

Thank You

Clinical Benefits of the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection from the ENTRAP Study Koen Keirse, MD RZ Tienen, Belgium